WOMEN'S HEALTH: MARKET FOR FEMALE URINARY INCONTINENCE DEVICES

104 Pages | 19 Exhibits | 2016 Analysis | Forecasts Through 2020

OVERVIEW:
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for minimally invasive female urinary incontinence devices. Markets covered include urethral bulking agents, urethral slings, and neuromodulation devices.

FEMALE URINARY INCONTINENCE MARKET HIGHLIGHTS

  • Urinary incontinence affects more than 200 million people worldwide.
  • The global market for female urinary incontinence products totaled more than $643.7 million in 2015, with sales of neuromodulation systems accounting for the largest share.
  • From 2015-20, the value of the global market for female urinary incontinence devices is projected to grow at a CAGR of 2.6%, reaching an estimated $733.3m in 2020.
Key Questions Answered
  • What are the key drivers and limiters to the female urinary incontinence devices market?
  • Which competitors are leading the market and introducing new technology?
  • How are technological advancements impacting market growth?
  • Which areas of the market are experiencing dynamic growth?
  • How are mergers and acquisitions affecting the market shares of leading competitors?


TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Methodology

Exhibit ES-1: Global market for female urinary incontinence devices, combined market forecast, 2015-20 
Exhibit ES-2: Global market for female urinary incontinence devices, share by product type, 2015 

1. FEMALE URINARY INCONTINENCE CLINICAL OVERVIEW

1.1 Anatomy of the Urinary System
1.2 Types of Urinary Incontinence
	1.2.1 Stress urinary incontinence 
	1.2.2 Overactive bladder and urge incontinence 
1.3 Treatment for Urinary Incontinence 
1.4 Stem Cell Research
1.5 Bibliography

Exhibit 1-1: Estimated worldwide prevalence of overactive bladder, 2008, 2013, and 2018

2. INJECTABLE URETHRAL BULKING AGENTS FOR STRESS URINARY INCONTINENCE

2.1 Reimbursement 
2.2 Safety and effectiveness 
2.3 Contraindications
2.4 Selected products
	2.4.1 Carbon Medical Technologies 
	2.4.2 Cogentix 
	2.4.3 Merz Aesthetics/Merz Pharma 
	2.4.4 Other urethral bulking agents not yet approved in the US
		2.4.4.1 Bulkamid 
		2.4.4.2 Urolastic 
		2.4.4.3 Urolon
	2.4.5 Alternative agents being researched 
2.5 Market analysis 
2.6 Competitive analysis
2.7 Bibliography

Exhibit 2-1: Analysis of selected urethral bulking agents, 2016
Exhibit 2-2: Injectable urethral bulking agents, global market forecast, 2015-20 
Exhibit 2-3: 2015, Global urethral bulking agents market, share by supplier

3. URETHRAL SLING SYSTEMS FOR STRESS URINARY INCONTINENCE

3.1 Safety Concerns and Legal Issues
	3.1.1 US safety reviews
	3.1.2 Safety reviews outside the US
	3.1.3 Mesh lawsuits
	3.1.4 Conclusions
3.2 Selected Products 
	3.2.1 CR Bard
	3.2.2 Boston Scientific
	3.2.3 CL Medical 
	3.2.4 Caldera
	3.2.5 Coloplast 
	3.2.6 Cousin Biotech 
	3.2.7 Ethicon/Johnson & Johnson
3.3 Market Analysis 
	3.3.1 Procedure volumes 
		3.3.1.1 United States
		3.3.1.2 European Union 
		3.3.1.3 Japan 
		3.3.1.4 Rest of World
	3.3.2 Market forecast
		3.3.2.1 United States
		3.3.2.2 5EU 
		3.3.2.3 Rest of World
	3.3.3 Competitive analysis 
3.4 Bibliography

Exhibit 3-1: The three main types of midurethral slings for SUI
Exhibit 3-2: Retropubic and transobturator approaches 
Exhibit 3-3: Ongoing postmarket studies of single-incision sling systems for urinary incontinence
Exhibit 3-4: Independent reviews conducted outside the US of the evidence for the safety/efficacy of urogynecologic surgical mesh implants
Exhibit 3-5: Selected synthetic urethral sling systems, 2016
Exhibit 3-6: Urethral sling placements, procedure volumes forecast, 2015-20
Exhibit 3-7: Urethral sling systems, market forecast, 2015-20 
Exhibit 3-8: 2015, Urethral slings market, global, share by supplier
Exhibit 3-9: 2015, Urethral slings market, US, share by supplier
Exhibit 3-10: 2015, Urethral slings market, 5EU, share by supplier
Exhibit 3-11: 2015, Urethral slings market, Rest of World, share by supplier

4. NEUROMODULATION SYSTEMS TO TREAT OVERACTIVE BLADDER 

4.1 Sacral Nerve Stimulation 
4.2 Percutaneous Posterior Tibial Nerve Stimulation 
4.3 Selected Neuromodulation Systems for Overactive Bladder
	4.3.1 Axonics Modulation Technologies 
	4.3.2 Bioness
	4.3.3 BlueWind Medical
	4.3.4 Cogentix Medical
	4.3.5 FemPulse 
	4.3.6 Medtronic
		4.3.6.1 InterStim
		4.3.6.2 NURO
	4.3.7 Nuvectra
	4.3.8 StimGuard 
4.4 Market Analysis 
4.5 Competitive Analysis 
4.6 Bibliography

Exhibit 4-1: Selected neuromodulation systems for treatment of overactive bladder 
Exhibit 4-2: Neuromodulation systems for treatment of overactive bladder, global market forecast, 2015-20
 
5. OTHER TECHNOLOGIES FOR TREATING FEMALE STRESS URINARY INCONTINENCE
 
5.1 Artus Active Implant
5.2 Lyrette Transurethral Radiofrequency System 
5.3 Vesair Bladder Control System 

APPENDIX: COMPANY LISTING


COMPANIES COVERED:

  1. Allergan, Inc.
  2. American Medical Systems, Inc./Endo International plc
  3. Aqlane Medical BV
  4. Axonics Modulation Technologies, Inc.
  5. C.R. Bard, Inc.
  6. Bioness, Inc.
  7. Boston Scientific Corporation
  8. BlueWind Medical Ltd.
  9. Caldera Medical, Inc.
  10. Carbon Medical Technologies, Inc.
  11. CL Medical
  12. Cogentix Medical
  13. Coloplast Corporation
  14. Cook Medical, Inc./Cook Group, Inc.
  15. Cousin Biotech
  16. Ethicon, Inc./Johnson & Johnson
  17. FemPulse, LLC
  18. Innovacell Biotechnologie AG
  19. Mayumana Healthcare BV
  20. Medtronic, Inc.
  21. Merck & Company, Inc.
  22. Merz Aesthetics, Inc./Merz Pharma GmbH & Co. KGaA
  23. MyoPowers Medical Technologies SA
  24. Nuvectra Corporation
  25. Promedon SA
  26. Solace Therapeutics, Inc.
  27. Specialty European Pharma Ltd.
  28. StimGuard LLC
  29. Stimwave LLC
  30. Teva Pharmaceutical Industries Ltd.
  31. TFS Surgical
  32. Urogyn BV
Contact Us

Need help finding medtech research? Let us help you!